Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ephedrine supplements label warning against use for weight loss urged by pediatricians.

This article was originally published in The Tan Sheet

Executive Summary

EPHEDRINE LABEL WARNING AGAINST USE FOR WEIGHT LOSS SUGGESTED by the American Academy of Pediatrics in Aug. 15 comments to FDA. Noting the agency has proposed that ephedrine-containing dietary supplements should not be allowed to carry weight loss claims, AAP recommends additional "inclusion of statements advising that such products are not intended for use as an intervention for weight loss." The group supports "full disclosure labeling of such products and oppose[s] any suggestive claims designed to make these products more appealing to children, particularly adolescents."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087500

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel